Trial Profile
A retrospective study of anlotinib combined chemotherapy in HER-2 negative metastatic breast cancer patients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 10 Feb 2023
Price :
$35
*
At a glance
- Drugs Catequentinib (Primary) ; Docetaxel; Etoposide; Gemcitabine; Vinorelbine
- Indications Advanced breast cancer; HER2 negative breast cancer
- Focus Therapeutic Use
- 10 Feb 2023 New trial record